MILLENIUM DEVELOPMENT GOALS (MDGs) MDG 6 Combat HIV / AIDS, malaria and other diseases This report shall focus on MDG 6. GOAL MDG 6 combats AIDS and other diseases.
MILLENIUM DEVELOPMENT GOALS (MDGs) MDG 6 Combat HIV / AIDS, malaria and other diseases This report shall focus on MDG 6. GOAL MDG 6 combats AIDS and other diseases.
MILLENIUM DEVELOPMENT GOALS (MDGs) MDG 6 Combat HIV / AIDS, malaria and other diseases This report shall focus on MDG 6. GOAL MDG 6 combats AIDS and other diseases.
Submitted By: Trivenika Avasthi (E006) Pallav Parkhe (E042) Nikhil S (E045) Geetansh Choudhary (E056) Ramit Mohan Chaudhuri (E060) Jayanthi L V B Uday Kumar (E061) Vineeth Jayendranath (E062)
1 | P a g e
CONTENTS INTRODUCTION...2 GOAL......2 HIV/AIDS....2 TRENDS OF HIV/AIDS GOVERNMENT PROGRAMS ANALYSIS OF EFFORTS MALARIA4 TRENDS OF MALARIA GOVERNMENT PROGRAMS ANALYSIS OF EFFORTS TUBERCULOSIS6 TARGETS BY 2015 GOVERNMENT PROGRAMS RESPONSE OF CORPORATE...7 CORPORATES IN INDIA WORKING TOWARDS HIV/AIDS..8 ANALYSIS OF EFFORTS ROADMAP FOR THE FUTURE RECOMMENDATIONS CORPORATES IN INDIA WORKING TOWARDS MALARIA...12 ANALYSIS OF EFFORTS ROADMAP FOR THE FUTURE CORPORATES IN INDIA WORKING TOWARDS TUBERCULOSIS14 ANALYSIS OF EFFORTS ROADMAP FOR THE FUTURE FINAL RECOMMENDATIONS..17 2 | P a g e
Introduction The Millennium Development Goals (MDGs) are eight international development goals that were officially established following the Millennium Summit of the United Nations in 2000, following the adoption of the United Nations Millennium Declaration. All 189 United Nations member states and at least 23 international organizations have agreed to achieve these goals by the year 2015. This report shall focus on MDG 6.
GOAL MDG 6: Combat HIV/AIDS, malaria and other diseases HIV/AIDS Relevance of the MDG Deeply concerned with the global HIV/AIDS epidemic, its devastating scale and impact, constitutes a global emergency and one of the most formidable challenges to human life and dignity, as well as to the effective enjoyment of human rights. This undermines social and economic development throughout the world and affects all levels of society national, community, family and individual. By the end of the year 2000, 36.1 million people worldwide were living with HIV/AIDS, 90 per cent in developing countries and 75 per cent in sub-Saharan Africa. AIDS afflicted all people, rich and poor, without distinction of age, gender or race, further people in developing countries are the most affected and that women, young adults and children, in particular girls, are the most vulnerable, which undermined Millennium Development goal concerned with empowering women and promoting gender equality. The continued epidemic of HIV/AIDS would also constitute a serious obstacle to the realization of the global development goals
HIV/AIDS: The trends across the globe The part of the world most impacted by HIV, sub-Saharan Africa, has cut the number of new infections by 50% between 2001 and 2011. In the Middle East and North Africa however, the number of people newly infected with HIV increased by 35% between 2001 and 2011, and the rate of new HIV infections continues to rise in Eastern Europe and Central Asia. In the sub- continent region countries like Indonesia, Pakistan and Bangladesh have seen a rise in the no. of new cases reported. HIV/AIDS: The trends in India The National AIDS Control Organization estimated that 2.39 million people live with HIV/AIDS in India in 2008-09. HIV epidemic in India is to a large extent confined among the High Risk Groups, i.e., Female Sex Workers, Injecting Drug Users, Men who have Sex with Men and Transgender. The prevalence of HIV/AIDS is about 20 times higher in these groups as compared 3 | P a g e
to that among the general population. Based on HIV Sentinel Surveillance 2008-09, it is estimated that India has an adult prevalence of 0.31 percent with 23.9 lakh people infected with HIV, of which, 39 percent are female and 3.5 percent are children.. However, epidemiological analysis revealed that the number of new annual HIV infection cases has declined by more than 50 percent during the last decade. It is estimated that India had approximately 1.2 lakh new HIV infected persons in 2009, as against 2.7 lakh in 2000. At all India level, the estimated new HIV infections in 15+ years population also has shown a declining trend and registering a decline by 20% during 2006-2009 (from 1,50,672 in 2006 to1,20,668 in 2009).
Indicator 1: HIV prevalence among pregnant women aged 15-24 years Among pregnant women of 15-24 years, the prevalence of HIV has declined from 0.86% in 2004 to 0.48% in 2008.
Indicator 2: Condom use rate of the contraceptive prevalence rate (Condom use to overall contraceptive use among currently married women, 15-49 years, percent) According to NFHS III (national family health survey) Condom use rate of the contraceptive prevalence rate (Condom use to overall contraceptive use among currently married women, 15- 49 years percent) was only5.2 % at all India level.
Indicator 3A: Condom use at last high risk sex (Condom use rate among non-regular sex partners 15-24 yrs.) The Behavioral Surveillance Survey (BSS) conducted to monitor the changes in knowledge and behavior indicators indifferent risk groups with respect to HIV/AIDS indicates that Condom use among non-regular sex partners is quite prevalent. According to BSS conducted in 2001 & 2006, the national estimates for Condom use at last high-risk sex (%) -Proportion of population aged 15-24 years who used condom during last sex with non-regular partner registered a 19%increase from 51.9% in 2001 to 61.7% in 2006.
Indicator 3B: Percentage of population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS According to BSS, the national estimate for proportion of population aged 15-24 years with comprehensive correct Knowledge of HIV/AIDS in 2006 was 32.9 % reporting betterment from 2001 (22.2%).
Government Programmes: When HIV infection was discovered in India in1986, the health authorities set up the NACO which prepared an outline for National AIDS Control Programme (NACP) that was primarily funded by the World Bank and technically supported by WHO. 4 | P a g e
National AIDS Control Programme (NACP) The national response to HIV/AIDS in India over the last decade has yielded encouraging outcomes in terms of prevention and control of HIV. Analysis of epidemic projections revealed that the number of annual new HIV infections has declined by more than 50% during the last decade. This is one of the most important evidence on the impact of the various interventions under the National AIDS Control Programme and scaled-up prevention strategies. Prevention and Care, Support & Treatment (CST) form the two key pillars of all the AIDS control efforts in India. Details of activities 1. Counseling and testing services 2. STI/RTI prevention and control component 3. Blood Safety Programme. 4. Condom Social Marketing Programme 5. Information Education & Communication 6. Adolescent Education Programme (AEP)
Analysis of the efforts The government in tandem with NGOs has been taking concrete steps in the direction of awareness and promotion about the use of condoms. The government has also set up National AIDS research Center in Pune to facilitate HIV vaccine development and testing in India. NACP has been especially successful in the area of Prevention of perinatal transmission of HIV. The programme currently falls under the purview of the state and needs to be decentralized so that it becomes more cost effective as not all states are uniformly affected by epidemic .No concrete steps have been taken in terms of educating the masses on the relevance of HIV testing. Though Indian companies marketed the ARV treatment with considerable price reduction it has still been largely out of reach of the common man. Moreover, the penetration of the treatment at grass root level is very poor. Since sexual transmission is the major reason for AIDS transmission, those afflicted are still marginalized in society and concrete steps have to be taken to initiate their rehabilitation into the society.
MALARIA
Relevance of the MDG: Malaria imposes great socio-economic burden on humanity, and with six other diseases (diarrhoea, HIV/AIDS, tuberculosis, measles, hepatitis B, and pneumonia), accounts for 85% of global infectious disease burden. Malaria afflicts approx. 90 countries and territories in the tropical and subtropical regions and almost one half of them are in Africa, South of Sahara. About 36% of the world population (i.e., 2020 million) is exposed to the risk of contracting malaria. In the South eastern Asian Region of WHO, of approx.1.4 billion people living in 11 countries (land area, 8,466,600 km2; i.e., 6% of global area), 1.2 billion are exposed to the risk 5 | P a g e
of malaria, most of whom live in India. However, Southeast Asia contributed to only 2.5 million cases to the global burden of malaria. Of this, India alone contributed 76% of the total cases. Target 6C: Have halted by 2015 and begun to reverse the incidence of malaria and other major diseases Indicators 6.6 Incidence and death rates associated with malaria 6.7 Proportion of children under 5 sleeping under insecticide-treated bed nets 6.8 Proportion of children under 5 with fever who are treated with appropriate anti-malarial drugs WORLD PROGRES The global estimated incidence of malaria has decreased by 17 per cent since 2000, and malaria-specific mortality rates by 25 per cent. In the decade since 2000, 1.1 million deaths from malaria were averted. Countries with improved access to malaria control interventions saw child mortality rates fall by about 20 per cent. Thanks to increased funding, more children are sleeping under insecticide-treated bed nets in sub-Saharan Africa. INDIAs PROGRES While in some isolated local areas it is possible to meet the MDG but for the country as a whole we will definitely miss the deadline. This is true for the rural and urban malaria and other ecotypes as well. In 2010, malaria caused 46,800 deaths in India, according to the Institute for Health Metrics and Evaluation study. A whopping 80.5 per cent of the 1.2 billion people in India currently live in malaria prone areas. Not surprisingly, it is considered highly unlikely that the country will meet the Millennium Development Goals (MDG) to combat malaria by 2015. The National Malaria Eradication Programme was launched in 1958. However, the malaria related strategy has undergone various changes since then. Since 2005-06, the malaria prevention and control activities are being implemented as a part of National Vector Borne Disease Control Programme (NVBDCP) under overarching umbrella of the National Rural Health Mission (NRHM).
6 | P a g e
GOVERNMENT PROGRAMMES National Vector Borne Disease Control Program (NVBDCP) Urban malaria scheme (UMS) Modified Plan of Operation (MOP) Also certain NGOs like LEPRA society and Janakalyan Pratisthan have worked extensively towards the control of malaria. Analysis OG efforts: Although the government has been and still is actively trying to eliminate the disease, there isnt active participation from the NGOs or corporates till now. Problems being faced: Inefficient and gaps in reporting the Maria incidences due to deficiencies in coverage, collection, and examination of blood smears and reporting systems. The data from the private clinics do get reflected in the Government data in many cases. Inaccesible areas cause deficiency in routine surveillance programmes Shortage of dedicated staff Widespread resistance of themalarial parasite to chloroquine Delaysin release of programme funds to endemic districts by states.
TUBERCULOSIS Relevance of the MDG: Tuberculosis has been chosen as an MDG target because detecting tuberculosis and curing it are key interventions for addressing poverty and inequality. Prevalence and deaths are more sensitive markers of the changing burden of tuberculosis than incidence (new cases), although data on trends in incidence are far more comprehensive and give the best overview of the impact of global tuberculosis control. Since tuberculosis is an airborne contagious disease, primary control is effected through finding and treating infectious cases and thus limiting the risk of acquiring infection. However, with rising rates of HIV infection, the number of TB cases is likely to rise, as people with HIV are more susceptible to TB. Target to achieve by 2015: The aim is to maintain at least a 70% case detection rate of new smear positive cases as well as maintain a cure rate of at least 85%. This needs to be done in order to achieve the TB-related targets set by the Millennium Development Goals for 2015 and to achieve TB control in the longer term. 7 | P a g e
India presently is on target set by the MDG goals of 70 % case detection rate and 85% cure rate. In 2010 the Case detection rate was 72% and treatment success rate 87%. In 2nd quarter 2011 the Case detection rate was 78.6% and the success rate was 87.7%. But it is facing fresh issues due to the emergence of : a) Multidrug-resistant (MDR-TB) tuberculosis b) Extensively drug-resistant (XDR-TB) tuberculosis which has emerged as a fresh threat to the initiatives against TB eradication, not only in India, but all over the world. Government Programmes RNTCP- Revised National Tuberculosis Control Program DOTS- Directly Observed Treatment-Short course DOTS-plus
RESPONSE OF CORPORATE
Why should corporate be involved? As India is rapidly becoming a foreign investment sweet spot, there are potential economic repercussions of the HIV/AIDS, malaria and other epidemics. AIDS particularly kills young and middle-aged adults during their peak productive years. By reducing the labor supply and disposable incomes, a generalized epidemic can have broad macroeconomic effects, dampening markets, savings rates, investment, and consumer spending. Thus, by early years of 21st century, corporate across the country realized the dangerous consequences of these diseases and have started to put their efforts towards controlling this epidemics. Their main aim has been to bring awareness among their employees and the local communities as these factors were majority contributors towards their profits. So they have come up with various programs to create awareness about HIV/AIDS, malaria and other diseases in these groups. The following text brings forward a few glimpses of the efforts put in by various companies.
Corporate in INDIA working towards HIV/AIDS:
PepsiCo India HIV/AIDS Initiative: PepsiCo India embarked on the HIV / AIDS journey in 2005, along with their Technical partner The International Labor Organization (ILO), with the purpose of spreading awareness amongst all their stakeholders. They have built the whole program in a manner to build capacity within and externally and have focused on the Each one Teach one approach to ensure sustainability. They started the program by cascading HIV / AIDS awareness amongst their employees. This 8 | P a g e
was progressively enhanced to cover other stakeholders including spouses of employees, business partners, distributors, contractual workers, and their bottling partners. They further strengthened the impact of their efforts through community outreach programs where they leveraged their NGO partners across the country. PepsiCo India has been awarded TERI Corporate Award for Business Response to HIV/AIDS in 2009.
Reliance Industries Limited (RIL) Reliance Industries Limited (RIL) joined hands with the United Nations Programme on HIV/AIDS (UNAIDS) to ensure equal access to HIV services for the poor across India. The Reliance HIV and AIDS program has two components: awareness and education, and treatment and support.
Awareness and Education Reliance tried to bring awareness among its employees and the local community around its plant in Gujarat by conducting weekly seminars and mass community awareness programs. For this it collaborated with lok vikas sanstha and Gujarat State Network of People Living with HIV Treatment and Support Reliance had setup a treatment centre at Hazira to serve the local communities. The center provides a number of medical tests free for HIV-positive patients at a heavily subsidized cost. Patients seeking treatment for sexually transmitted infections receive counseling on such topics as modes of HIV transmission, the relationship between HIV and sexually transmitted infections, and the use of condoms. The center also provides antiretroviral therapy.
Modicare Foundation It was set up by Mr. Samir Modi in 1996 with the commitment to prevent the spread of HIV/AIDS, enhance awareness and erase the myths and misconceptions surrounding it. Key projects Workplace HIV/AIDS Intervention Program (2000 onwards) Under this program, the foundation has worked with industries like Jindal Iron & Steel Ltd (Tarapur & Vasind), Jindal Stainless Ltd (Hissar & Jajpur), Godrej, Blue star, Indofil Chemicals, Nike Shoes, Polar Group, Moja Shoes, JCB, Sandhar, ITC, Technova Graphics, Colgate, Fortis Healthcare Ltd etc, MphasiS, Tata Consultancy Services etc. The Foundation has been associated with various wings of the Armed Forces (Indian Army, Airforce and Navy) and has developed tools and conducted awareness and peer education sessions with them.
9 | P a g e
Ambassadors of Change Program (Life Skills Program for Adolescents) -1997 onwards The aim of the program is to encourage adolescents to make informed choices related to growing up and HIV/AIDS, enabling them as well as their environments. The Foundation has trained more than 50,000 adolescents through this programme. Regular sessions are conducted with adolescents in government and public schools, colleges using methodologies that are interactive, creative, fun and inspiring The Sponsorship Program (1997 onwards) It provides medical and nutritional support to people infected with the virus and their families. Modicare Foundation has also established Support Groups of People living with HIV&AIDS (PLWHAs) in order to provide psychosocial support to people infected with HIV as well as their families. Voluntary Counseling and Testing Center (2002 onwards) Voluntary Counseling and Testing Center established by the Modicare Foundation in collaboration with MAMC (Maulana Azad Medical College) and D-SACS ( Delhi State AIDS Control Society) at the Lok Nayak Hospital, a government facility located in New Delhi, provides a safe space where people can obtain information on HIV. Since its inception, the center has worked with approximately 8000+ cases and is rated to be one of the best VCTC with trained professionals managing it. The center is also linked with the ARV clinic at the hospital from where clients can obtain referrals and access medical treatment. Care and treatment of children (2007 onwards) With the support of Clinton Foundation, Modicare Foundation worked as Coordinating Agency for 5 Delhi based NGOs on the National Pediatric Program. This was implemented for linking infected children to government ART centers for CD4 cell estimation, pre- ART evaluation and administering ART/OI drugs as required. Empowering Women through Gender Resource Centre (GRC) (2008 onwards) Recognizing the strength of the Foundation, the Government of N.C.T. of Delhi has appointed Modicare Foundation as a "Mother NGO" to facilitate monitoring and supervision of the activities and functions of various GRCs located in the different parts of Delhi. These GRCs are envisaged as an instrument to bring social, economic and legal empowerment of women particularly those belonging to the underprivileged sections of the society.
10 | P a g e
SWAYAM (Sept 2008 onwards) Modicare Foundation is currently managing a Targeted Intervention project named SWAYAM started from September 2008 to work with MSM in the North district of Delhi. The programme is funded by D-SACS (Delhi-State AIDS Control Society) with a goal to improve the sexual health of males who have sex with males and reduce the chances of STI and HIV infection among this target group REVAMP (June 2008 onwards) Modicare Foundation has developed a new partnership with CARE India Trust with the support of NACO (National AIDS Control Organisation) to implement a project call REVAMP (Reducing Vulnerability of AIDS among Migrants Population) in three potential sites of South Delhi. The primary objective of this project is to increase awareness of HIV& AIDS, decrease risky sexual behaviors, and create demand for services among migrants. ACC limited: It announced a Workplace policy for HIV/AIDS that protects the fundamental human rights of employees who may unfortunately become affected by HIV/AIDS, while also ensuring that these affected persons get proper care and treatment. They set up an Anti Retroviral Treatment Centre for HIV/AIDS treatment in Wadi, Karnataka. Karnataka also happens to be a state where the virus is highly prevalent. The center includes a Voluntary Counseling and Testing Centre (VCTC). Their aim is to develop the skill and capability to run this center at Wadi as a world-class facility for the benefit of the public, with the assistance of NACO, CII and prestigious medical institutes such as CMC Vellore. INDIAN OIL CORPORATION Indian Oil in its Mission states To enrich the quality of life of community and has a policy of non-discrimination in relation to HIV/AIDS infection for employment at recruitment level, as well as training, transfer or promotion. Indian Oil has associated itself with Bill & Melinda Gates Foundation to address the issue of spread of HIV infection. Their state offices have been advised to extend all necessary assistance to Project Directors of State AIDS control Society of National AIDS Control Organization, Ministry of Health & Family Welfare, Government of India. These retail outlets are also good rallying point for dissemination of HIV/AIDS related messages including dispensing of condoms. 11 | P a g e
TATA STEEL Tata Steel Ltd. started AIDS Awareness Programmes both in the workplace and in the community. Tata Steel Ltd reaffirms its commitment to UNAIDS Theme for 2011 2015 Getting to Zero. The Company developed effective responses to the epidemic by building special infrastructure and the establishment of the AIDS Cell, Tata Steel. This was subsequently upgraded to Nodal Centre for AIDS with the task of bringing focused efforts across Tata Steel as well as networking with other Medical Institutions, Governmental & International agencies. PPTCT programme is a service component offered to pregnant Women Living with HIV/AIDS at Tata Main Hospital in partnership with Sneh Kendra. Since past 5 years 23 HIV+ women have delivered at TMH and none of the babies have tested HIV+. Tata steel has received TERI Corporate Award for HIV/AIDS May 2008 for Sneh Kendra. TCIF Golden Certificate was given in 2007. Award for Corporate Social Responsibility in Public Health conferred by the US-India Business Council (USIBC), Population Services International (PSI) and The Center for Strategic and International Studies (CSIS) for outstanding contribution to combat HIV/AIDS in March 2007. Global Business Coalition on HIV/AIDS Award 2003 for its initiatives on HIV/AIDS in the community.
Apollo Tyres The companys HIV-AIDS Awareness and Prevention Programme is targeted at 4 key stakeholders employees, customers, business partners and community. Under this, Apollo undertakes awareness and prevention sessions and provides voluntary, confidential testing and support. In India, the company runs 21 Health Care Centers in prominent transshipment hubs for the commercial vehicle community. Each of these centers is equipped with qualified doctors, paramedic staff and counselors, and also has its own network of peer educators who work with the community to effect behavior change.
ANALYSIS OF EFFORTS: Success: Outreach: Though, the outreach of these corporate is limited to only their stakeholders. The sheer number of stakeholders for corporations such as Reliance constitutes a significant change Partnering: Corporates have not only partnered with NGOs but also expanded links with existing health services is important it enables the target group to gain access to services not provided by the program and also avoids duplicating services. Innovation: The corporate bring about innovation in terms of tackling problems such as disease control. With leaders in the field of expertise entering to alleviate causes of HIV, malaria and other diseases. 12 | P a g e
Challenges: Lack of infrastructural support by the government: Many corporates have focused onto providing antiretroviral treatments to patients but lack of clinics to dispense these treatments and paltry penetration have led to the success of these efforts being undermined
Retention of outreach workers: While the corporate have encountered success in terms of partnering the retention of workers is a huge challenge, moreover once a worker leaves a huge cost is incurred in terms of training and hiring a new recruit. Sensitizing industry stakeholders: Many companies have not yet realized the enormity of the HIV and AIDS problem, its repercussions, and the high cost of inaction. Message fatigue: Messages became ineffective with too much repetition. Moreover, repeated interventions targeted groups saddled them with negative branding because of the stigma associated with HIV and AIDS. Roadmap for the future: Corporate efforts are at this point limited only to their direct stakeholders and no efforts for targeting high risk groups. Specific efforts towards pregnant women not addressed. The indicator has not been addressed Recommendations: Take early decisive action. Companies that carry out HIV and AIDS interventions do so to safeguard the health of their employees and because these efforts accord with their values and mission. Such efforts can meet resistanceat the corporate level, at the workplace, and in the local communityespecially where action is taken early to stem an epidemic before it has become generalized, when the perceived risk may be low. But taking early decisive action on burden of death and disability and averts the high cost of treating and caring for large numbers of people living with AIDS. Document cost and effectiveness. There is much to learn from actions taken by businesses to prevent HIV and treat and care for AIDS patients. It is important to learn by doing. But beyond this, formal, independent evaluation is needed to assess the effectiveness of these interventions. Better monitoring and evaluation will help in planning and implementing programs, in identifying gaps, and, importantly, in sustaining, scaling up, and expanding initiatives.
Corporate in INDIA working towards MALARIA:
Ranbaxy: Ranbaxy Laboratories Limited (Ranbaxy) launched Indias first new drug, Synriam, for the treatment of uncomplicated Plasmodium falciparum malaria, in adults, dedicating the New Age Cure for Malaria to the Nation, on World Malaria Day. 13 | P a g e
Launched on World Malaria Day as part of Ranbaxys corporate social responsibility (CSR), Synriam is expected to become a part of Indias national malaria eradication programme. The drug has been developed by Ranbaxy Laboratories, owned by Japans Daiichi Sankyo Co., in collaboration with the department of science and technology (DST), Government of India, and support from the Indian Council for Medical Research. Godrej Consumer Products: Godrejs HIT insecticide spray has played a significant role in increasing awareness about the disease and its prevention, with its HIT Kill Malaria campaign. The campaign initiated in 2010, engages with a range of activities in schools and housing societies, along with the municipal corporation in various cities. Apart from an interactive website that encourages one to join the cause against malaria and never miss an opportunity, the brand has included fun ways to contribute to the cause. Visitors can share their stories of lost opportunities and get featured on the site, as well as be a part of the Do Good initiative. For every person who joined the Do Good campaign, HIT donated Rs. 2 towards its Corporate Social Responsibility tasks that include creating awareness, cleaning up and fumigation operations in slums.
Pfizer: Pfizer has dedicated itself to a platform of innovative, socially responsible, and commercially viable activities to help close the malaria treatment gap Pfizer collaborates with the WHO and its Special Programme for Research in Tropical Diseases (WHO/TDR) to target malaria and other neglected tropical diseases. In April 2009, Pfizer and Medicines for Malaria Venture (MMV) signed an agreement which gives MMV access to Pfizer's vast chemical compound library in order to test approximately 200,000 compounds for activity against P. falciparum. Such public-private research partnerships are vital to overcoming the health challenges of developing countries. Pfizer partners with leading NGOs to find promising interventions that improve the utilization and effectiveness of malaria treatment. At the 2006 Clinton Global Initiative, Pfizer announced a five-year program (2007-2012), Mobilize Against Malaria, focused on improving access to prompt and effective treatment, on preventing infection and the spread of malaria by improving symptom recognition, treatment, and referral through local grassroots training, education and awareness. ANALYSIS OF THE EFFORTS As per the data and progress report, it is evident that India will miss its MDG target relevant to Malaria. Analysis of efforts Almost none of the corporate in India except for the pharmaceutical companies are targeting malaria dedicatedly. The rest of the companies address the issue with the help of integrated health camps, seminars, awareness campaigns. Although these initiatives are appreciable, they 14 | P a g e
are not solely focussed on the issue of Malaria. Therefore these initiatives cannot be termed as long term approach towards achieving eradicating Malaria.
Roadmap to the future 1. Increase the inter-sectorial coordination between the government, NGOs and corporate. 2. Improving the data collection reporting systems. 3. Reduce the delay in implementing programmes, releasing and monitoring funds. 4. Develop efficient and affordable medicines preferably vaccines that will help reduce the malaria incidences like in the case of polio. 5. Increase the coordination between Indian and foreign NGOs working towards the MDGs 6. Improve the efforts by corporate and NGOs in such a manner that they are sustainable and have a long term approach.
Corporate in INDIA working towards TUBERCULOSIS: Microsoft Research Microsoft Research developed biometric devices to track the treatment of patients. These devices are used in many countries including India in implementing DOTS. Microsoft has adopted a philanthropist approach. NTPC Identification of TB patient in 25-30 kms vicinity of project by NTPC medical team under RNTCP. Free treatment through directly observed Treatment cum designated microscopy centre (DOTs cum DMC) Mobile Van to doorsteps at 12 NTPC stations Spreading TB awareness through mobile vans More than 18000 patients registered for treatment ,2700 started treatment and 2100 completed treatment Novartis Sandoz, together with its parent company Novartis, is taking a stand against TB and is the main provider of TB drugs to the World Health Organization. For example, over the five-year period from 2004, Novartis donated gold-standard TB medicines to the World Health Organization for the treatment of half a million patients. Also, Novartis India is working with the Global TB Alliance for TB Drug Development on the development of a new drug for the treatment of TB. RIL The company has established a well-equipped DOTS therapy centre at Mora village.The purpose of this well equipped and adequately staffed centre is: 15 | P a g e
To identify and counsel persons with High Risk Behaviour. To provide a microscopy center and DOT therapy through the RNTCP To provide testing for Sputum examination. To spread the TB awareness in other neighboring industries in Surat . Analysis of the efforts : 148 million USD from 2002-2011 has been funded towards eradication of TB in India due to the initiatives taken by various organizations around the world. Due to their efforts there has been a decreasing Trend in TB Incidence. Despite the progress achieved under RNTCP and the initiatives taken by various organizations, TB incidence and mortality are still high, and an estimated 280,000 people died of TB in 2009. Reaching the un-reached is one of the important challenge as it necessitates innovative strategies for ensuring universal access to TB diagnostic and treatment facilities. Advocacy and communication strategies need to be inclusive of such efforts towards social mobilization for achieving universal access Urban areas still experience intense levels of TB transmission, where urban primary health care systems tend to be weaker and private health care predominates. Further reducing treatment default of patients put on treatment under Programme is another challenge in order to prevent drug Resistant TB. Linking HIV-infected TB patients to HIV care and support and implementing measures to prevent TB in HIV care settings need further strengthening. The Country needs to put in place more intensified measures on these areas to reach and maintain a desirable progress in reducing TB infections. Road map for the future: Take steps to reduce malnutrition which is a major factor for low immune system in children which subsequently makes them more vulnerable to diseases like TB. HIV/AIDS incidence is also a factor for low immune system. Thus HIV?AIDS TB co- infection can be reduced with decrease in HIV/AIDS. Setup laboratories, which have equipment to detect drug resistant forms of TB which would allow health bodies to better calculate the scale of the disease and resources can be focused on high risk areas. Pharmaceutical companies should try to make TB drugs which are low in cost. Final Recommendation: In all the interest areas, it must be ensured that there is sustained commitment and financing. A challenge for both the private and the public sector is to sustain the financing for prevention, treatment, and care. Continued financing is especially essential for treatment programs, which, once initiated, must not be interrupted. Developing strategies for sustaining programswhether run by businesses or by governmentwill become increasingly important, providing a strong impetus for greater private-public partnership and sharing of knowledge. 16 | P a g e
http://www.pfizer.com/responsibility/global_health/pfizer_malaria_partnership http://www.ranbaxy.com/ranbaxy-launches-synriam-indias-first-new- drug/. http://www.godrej.com/godrej/Godrej/Pdf/HillKillMalaria_250811.pdf case studies of world bank(2007)- Corporate responses to HIV/AIDS in india Articles in Journals: 1. Sharma,VP. Battling malaria iceberg incorporating strategic reforms in achieving Millennium Development Goals & malaria elimination in India 1. Indian J Med Res 136, December 2012, pp 907-925
2. Breman, J. G., M. S. Alilio, Nicholas J. White, Ashwani Kumar, Neena Valecha, Tanu Jain, and Aditya P. Dash. "Burden of malaria in India: retrospective and prospective view." Am. J. Trop. Med. Hyg., 77(Suppl 6), 2007, pp. 6978
3. Murray CJL, Lopez AD, 1996. Evidence-based health policylessons from the Global Burden of Disease Study. Science 274:740743.
4.Yadav RS, Bhatt RM, Kohli VK, Sharma VP, 2003. The burden of malaria in Ahmedabad city, India: a retrospective analysis of reported cases and deaths. Ann Trop Med Parasitol 97:793802.